GlassScriptPhysician profile
Nirav V Patel
NPI 1306293154
$2,516.79
in general payments reported to CMS, 2019-2025
25 companies · $658 in 2025
The $658 reported for 2025 was more than what 79% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.55 · 2022: $35.49 · 2023: $475 · 2024: $1,308 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925 · Consulting Fee: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.08 |
| Consulting Fee | $516.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $516.67 | 2024 | |
| Myriad Genetic Laboratories, INC. | $375.09 | 2023-2024 | Myrisk, Prolaris |
| Novartis Pharmaceuticals Corporation | $152.09 | 2024-2025 | |
| Blue Earth Diagnostics | $145.12 | 2024-2025 | Posluma |
| Sumitomo Pharma America, INC. | $142.01 | 2023-2025 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $134.61 | 2023-2025 | |
| Janssen Biotech, INC. | $121.30 | 2022-2025 | Erleada |
| Progenics Pharmaceuticals, INC. | $105.46 | 2023-2024 | Pylarify |
| Abbvie INC. | $101.58 | 2023-2025 | |
| Dendreon Pharmaceuticals LLC | $96.31 | 2024 | Provenge |
| Merck Sharp & Dohme LLC | $88.58 | 2025 | Lynparza, Keytruda, Welireg |
| Boston Scientific Corporation | $72.00 | 2023-2025 | Spaceoar Vue System - 10ml, Spaceoar System |
| Novocure INC. | $71.18 | 2019-2024 | Optune |
| Pfizer INC. | $60.88 | 2025 | |
| Bioprotect Medical, INC. | $57.92 | 2024-2025 | Bioprotect Balloon Implant System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $52.51 | 2024-2025 | Gelclair Concentrated Oral Gel |
| Sobi, INC | $36.62 | 2025 | |
| Janssen Pharmaceuticals, INC | $33.99 | 2024 | Xarelto |
| Incyte Corporation | $29.00 | 2025 | Monjuvi, Zynyz |
| Regeneron Healthcare Solutions, INC. | $26.13 | 2023 | Libtayo |
| Tolmar, INC. | $24.55 | 2024 | |
| Telix Pharmaceuticals | $21.63 | 2025 | Illuccix |
| Cvrx, INC. | $19.54 | 2025 | Barostim Neo System |
| Fresenius Kabi USA, LLC | $17.92 | 2022 | |
| Eisai INC. | $14.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.